Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1236 • ACR Convergence 2021
Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
Anthony Sebba¹, Duzhe Wang², Bochao Jia², Jason Troutt², Julie Birt², Amanda Quebe³ and Peter C Taylor⁴, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indanapolis, IN, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (BARI) is a Janus kinase (JAK)1/JAK2 inhibitor which provides improvements to clinical signs, symptoms, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis…
Abstract Number: 1252 • ACR Convergence 2021
Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies
Jeffrey Curtis¹, Joel Kremer², Dimitrios Pappas³, Lixia Zhang⁴, Erin Connolly-Strong⁵, Johanna Withers⁴, Viatcheslav Akmae⁴ and Alif Saleh⁴, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Albany Medical College, Latham, NY, ³CorEvitas, LLC, Waltham, MA, ⁴Scipher Medicine, Waltham, MA, ⁵Scipher Medicine, Austin, TX
Background/Purpose: A 23-feature blood-based molecular signature response classifier1 (MSRC) identifies rheumatoid arthritis (RA) patients who are unlikely to respond to tumor necrosis factor-ɑ inhibitor (TNFi)…
Abstract Number: 1472 • ACR Convergence 2021
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
Kazuhiro Yokota¹, Kojiro Sato², Yoshimi Aizaki³, Shinya Tanaka⁴, Miyoko Sekikawa⁴, Noritsune Kozu⁵, Yuho Kadono⁴, Hiromi Oda⁶ and Toshihide Mimura⁷, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Jichi Medical University, Tochigi, Japan, ³Saitama Medical University, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, ⁵Kozu Orthopaedic Clinic, Chiba, Japan, ⁶Department of Orthopaedic Surgery, National Hospital Organization Ibusuki Medical Center, Kagoshima, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama, Japan
Background/Purpose: We have previously reported that stimulation of mouse bone marrow–derived macrophages with a combination of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) induces…
Abstract Number: 1651 • ACR Convergence 2021
Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis
Salina Haville¹, Jennifer Seifert¹, Saman Barzideh¹, LauraKay Moss¹, Navin Rao², Alyssa Johnsen³, Jane Buckner⁴, Eddie James⁵, Sylvia Posso⁴, Gary Firestein⁶, David Boyle⁷, William Robinson⁸, V. Michael Holers⁹ and Kevin Deane¹⁰, ¹University of Colorado Denver, Aurora, CO, ²Janssen R&D, Spring House, PA, ³Janssen R&D, Princeton Junction, NJ, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁶University of California San Diego, San Diego, CA, ⁷University of California San Diego, La Jolla, CA, ⁸Stanford University, Palo Alto, CA, ⁹University of Colorado, Denver, CO, ¹⁰University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (IA). ACPA elevations…
Abstract Number: 1667 • ACR Convergence 2021
Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Yusuke Miwa¹, Yoshiaki Ohashi², Hajime Tomatsu³ and Yuko Mitamura⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²HMT Biomedical Inc., Yokohama, Japan, ³HMT Biomedical Inc., Chuo, Japan, ⁴Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: The odds of patients with rheumatoid arthritis (RA) experiencing depression is 1.42 (95% CI: 1.3–1.5; approximately 15% of patients) compared with healthy individuals. Diagnosis…
Abstract Number: 1683 • ACR Convergence 2021
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Belén Atienza-Mateo¹, Carlos Fernández-Díaz², Santos Castañeda³, Rafael Melero⁴, Francisco Ortiz-Sanjuán⁵, Ivette Casafont⁶, Sebastián C. Rodríguez-García⁷, Iván Ferraz-Amaro⁸, Miguel Ángel gonzalez-Gay⁹ and Ricardo Blanco¹⁰, ¹Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Reina Sofía, Murcia, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁵Hospital Universitario La Fe, Valencia, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ⁷Hospital Universitario Clinic, Barcelona, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe…
Abstract Number: 1699 • ACR Convergence 2021
The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome
Roxana Coras¹, Cameron Martino¹, Julia Gauglitz¹, Alan Jarmusch¹, Anupriya Tripathi¹, Francesca Cedola², Marta Fernandez-Bustamante¹, Meritxall Agustín-Perez¹, Maram Alharthi¹, Susan Lee¹, Abha Singh¹, Soo In Choi¹, Tania Rivera¹, Katherine Nguyen³, Tatyana Shekhtman¹, Tiffany Holt¹, Shahrokh Golshan¹, Rob Knight¹, Pieter C Dorrestein¹ and Monica Guma¹, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, Rome, CA, Italy, ³University of California San Diego, San Diego, CA
Background/Purpose: Fatigue is common symptom in rheumatoid arthritis (RA), associated with decreased quality of life and productivity. Fatigue mechanisms have not been well studied, hence,…
Abstract Number: 1892 • ACR Convergence 2021
Promotion of Autoimmune Arthritis via Tryptophan Metabolism and Production of the Bacterial-Derived Tryptophan Metabolite Indole
Brandon Trent¹, Meagan Chriswell², Widian Jubair¹ and Kristine Kuhn¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²UC Denver SOM, Denver, CO
Background/Purpose: Significant changes in gut bacterial richness and diversity occur during the development of inflammatory arthritis, in both murine models and human patients; however, the…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: 0011 • ACR Convergence 2021
Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Kentaro Noda, Bianca Dufner and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Prokineticin 2 (PK2) is a secreted protein involved in several pathological and physiological processes, including the regulation of inflammation, sickness behaviors, and the circadian…
Abstract Number: 0029 • ACR Convergence 2021
JAK1 Regulates Autophagy and Reinforces the Inflammatory and Autoimmune Potentials in Rheumatoid Arthritis Synovial Fibroblasts
Keita Ninagawa¹, Masaru Kato¹, Yuki Kudo², Masaru Yoshimura², Michihito Kono², Yuichiro Fujieda¹, Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Hokkaido University, Sapporo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is pathologically characterized by autoimmunity against citrullinated proteins, proliferative synovitis, and ultimately joint destruction. Synovial fibroblasts (SFs) are, when activated, capable…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
Abstract Number: 0156 • ACR Convergence 2021
Tenosynovitis Detected by Power Doppler Ultrasound: A Differential Feature of Patients with Seronegative Rheumatoid Arthritis
Einer Sanchez Prado¹, Santiago Ruta², Laura Cuellar¹, Sebastian Magri³ and Rodrigo Garcia Salinas⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital San Martin de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, La Plata, ⁴Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: It is known that seronegative rheumatoid arthritis has different characteristics from seropositive RA. Objectives: To estimate the frequency of rheumatoid arthritis (RA) in a…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].